Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Nephrol Dial Transplant. 2014 Mar;29(3):706-14. doi: 10.1093/ndt/gft502. Epub 2013 Dec 29.
Potent antibody depletion techniques have paved the way to successful ABO-incompatible transplantation. Considering its efficiency regarding IgG removal, the use of non-antigen-specific semi-selective immunoadsorption (IA) has been advocated. One attractive strategy to overcome the caveat of incomplete IgM depletion and to interfere with complement activation could be the adjunctive use of membrane filtration (MF) to enhance the removal of macromolecules.
To investigate the depletion efficiency of semi-selective IA plus MF, we conducted a randomized, controlled, cross-over trial including patients on regular IA treatment for indications outside recipient desensitization. According to the results of sample size calculation, 14 subjects were enrolled. Two treatment sequences, a single session of IA plus MF followed by IA alone after ≥7 days (and vice versa), were analysed.
IA plus MF markedly enhanced the median per cent reduction of ABO-specific IgM determined by flow cytometry (primary end point; 59 versus 23%, P < 0.001) and haemagglutination (2 versus 1 titre steps, P < 0.001), respectively. Combined treatment also substantially lowered C1q concentrations (86 versus 58% reduction, P < 0.001) and the functionality of classical complement as reflected by impaired in vitro C3 activation capability. IgG was strongly reduced without any additional effect of MF.
We demonstrate that the innovative strategy of combining MF with semi-selective IA may substantially increase IgM elimination and affect classical complement activation. Our findings suggest that this new treatment concept could be an efficient strategy for recipient desensitization in ABO- and HLA-incompatible transplantation.
强效抗体清除技术为 ABO 不相容移植的成功铺平了道路。考虑到其 IgG 清除效率,非抗原特异性半选择性免疫吸附(IA)的应用得到了提倡。一种克服不完全 IgM 清除和干扰补体激活的有吸引力的策略可能是辅助使用膜过滤(MF)来增强大分子的去除。
为了研究半选择性 IA 加 MF 的清除效率,我们进行了一项随机、对照、交叉试验,包括因受体脱敏以外的适应症而接受常规 IA 治疗的患者。根据样本量计算的结果,共纳入 14 名受试者。分析了两种治疗序列,即单次 IA 加 MF 后≥7 天单独 IA(反之亦然)。
IA 加 MF 显著提高了流式细胞术测定的 ABO 特异性 IgM 的中位数百分比降低(主要终点;59%对 23%,P < 0.001)和血凝(2 个对 1 个效价步骤,P < 0.001)。联合治疗还显著降低了 C1q 浓度(86%对 58%的降低,P < 0.001)和经典补体的功能,反映为体外 C3 激活能力受损。IgG 被强烈降低,而 MF 没有额外的作用。
我们证明了将 MF 与半选择性 IA 结合的创新策略可能会显著增加 IgM 的清除并影响经典补体的激活。我们的研究结果表明,这种新的治疗概念可能是 ABO 和 HLA 不相容移植中受体脱敏的有效策略。